Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors (Q46342083)

21 December 2017

title

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors (English)

1 reference

21 December 2017

main subject

phase I clinical trial

0 references

1 reference

21 December 2017

Lynda D Roman

object named as

Lynda Roman

1 reference

21 December 2017

author name string

Caroline I Piatek

1 reference

21 December 2017

Grace L Raja

1 reference

21 December 2017

Lingyun Ji

1 reference

21 December 2017

Barbara Jennifer Gitlitz

1 reference

21 December 2017

Tanya B Dorff

1 reference

21 December 2017

James Hu

1 reference

21 December 2017

Anthony B El-Khoueiry

1 reference

21 December 2017

Huyen Q Pham

1 reference

21 December 2017

Agustin A Garcia

1 reference

21 December 2017

publication date

6 November 2014

1 reference

21 December 2017

Cancer Chemotherapy and Pharmacology

published in

1 reference

21 December 2017

volume

1 reference

21 December 2017

issue

1 reference

21 December 2017

page(s)

1227-1234

1 reference

21 December 2017

Targeting the phosphoinositide 3-kinase pathway in cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2600-Z

10.1007/S00280-014-2600-Z

21 January 2018

Identifiers

DOI

1 reference

21 December 2017

release_exhq6fjjqrbcfe3ldmgvprcsyu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/exhq6fjjqrbcfe3ldmgvprcsyu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

21 December 2017